Published on 14 Mar 2024 on GuruFocus.com via Yahoo Finance
Eton Pharmaceuticals Inc (ETON) Reports Robust Sales Growth and Pipeline Progress in Q4 and ...
Revenue Growth: Q4 product sales and royalty revenue surged by 109% year-over-year to $7.3 million.Positive Cash Flow: ETON generated $0.4 million in operating cash flow in Q4, with a cash reserve of $21.4 million.Research and Development: R&D expenses slightly increased to $1.0 million in Q4, supporting progress in the company's drug pipeline.Net Loss: ETON reported a net loss of $2.3 million in Q4, attributed to a one-time payment and absence of prior year's licensing revenue.Balance Sheet Strength: Total assets stood at $31.7 million as of December 31, 2023, with a solid equity position.
Warning! GuruFocus has detected 4 Warning Sign with ETON.
